Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
Takeda Consumer Healthcare Looks to Stable, Sustainable Growth: President
Takeda Consumer Healthcare, a consumer healthcare spin-off of Takeda Pharmaceutical launched in April, is looking to deliver “stable and sustainable growth over a long period of time” to achieve its sales target of 100 billion yen, President Masashi Sugimoto told…
To read the full story
Related Article
- Takeda Consumer Healthcare President Sugimoto to Step Down following 1 Year Stint since Firm’s Inception
March 7, 2018
- Takeda Consumer Healthcare Spin-Off Now Up and Running
April 4, 2017
- Takeda’s Consumer Healthcare Biz Split-Off Going as Scheduled
February 21, 2017
- Takeda Consumer Healthcare Unit Aims for 100 Billion Yen Sales after Spin-Off
May 31, 2016
- Takeda to Spin Off Consumer Healthcare Unit, New Firm to Go Live in April 2017
February 4, 2016
BUSINESS
- Astellas on Track to Hit 30% Margin Goal Early after Strong H1 Scorecards
November 5, 2026
- Nxera Inks US$1.47 Billion Deal with AbbVie for IBD Drug
November 5, 2026
- Kissei Might Revise Midterm Targets as Tavneos Faces Approval Revocation
November 5, 2026
- Boehringer, Lung Cancer Society Launch 5-Year Hernexeos Real-World Study
November 5, 2026
- ASKA Snags Japan Rights to Minghui’s TED Therapy
November 5, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…